Table S1-S15 from Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy

Le résumé fourni par la source

Supplementary Table 1 summarizes the lines of therapy administered prior to CAR T cell therapy. Supplementary Table 2 presents myeloma parameters and additional laboratory findings obtained immediately before the initiation of lymphodepleting chemotherapy of the index patient. Supplementary Table 3 details the dosing regimens of the drugs used to treat parkinsonism following CAR T cell therapy. Supplementary Table 4 lists the amino acid sequences of the α and β chains of the top expanding T cell clones during parkinsonism. Supplementary Table 5 reports the differentially expressed genes between CSF samples obtained on day 30 and day 43. Supplementary Table 6 reports the differentially expressed genes between CSF samples obtained on day 43 and day 57. Supplementary Table 7 outlines disease characteristics, prior therapies, and CAR T dynamics in the control patient group. Supplementary Table 8 summarizes the baseline disease characteristics of the index patient at primary diagnosis. Supplementary Table 9 provides the markers used in the multiplex assay. Supplementary Table 10 lists the primer sequences used for the CAR integration assay. Supplementary Table 11 compiles the quality-filtering metrics applied to each sample used for single-cell sequencing. Supplementary Table 12 presents all markers identified for each cell cluster in the complete dataset of the index patient. Supplementary Table 13 presents all markers identified for each cell cluster within the T cell subset of the index patient. Supplementary Table 14 summarizes the markers detected in early post-CAR T samples of the index patient and control subjects, as well as in the pre-CAR T samples. Supplementary Table 15 lists the gene signatures used to calculate the IFN-I and IFN-II module scores. Supplementary Table 16 shows the structure of the sequencing data deposited in the European Genome-phenome Archive.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.